Compare FANG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FANG | EW |
|---|---|---|
| Founded | 2007 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4B | 50.2B |
| IPO Year | 2012 | 1999 |
| Metric | FANG | EW |
|---|---|---|
| Price | $187.33 | $84.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 21 |
| Target Price | ★ $194.89 | $96.47 |
| AVG Volume (30 Days) | 3.1M | ★ 4.0M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.73 | 1.83 |
| Revenue | ★ $15,026,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | N/A | $13.39 |
| Revenue Next Year | $8.29 | $9.78 |
| P/E Ratio | ★ $32.63 | $46.31 |
| Revenue Growth | ★ 35.79 | 11.55 |
| 52 Week Low | $114.00 | $65.94 |
| 52 Week High | $187.05 | $87.89 |
| Indicator | FANG | EW |
|---|---|---|
| Relative Strength Index (RSI) | 67.42 | 53.27 |
| Support Level | $136.41 | $81.39 |
| Resistance Level | N/A | $87.22 |
| Average True Range (ATR) | 6.42 | 2.27 |
| MACD | 0.32 | -0.06 |
| Stochastic Oscillator | 94.79 | 55.42 |
Diamondback is a crude oil and natural gas exploration and production firm whose operations represent a pure-play in the US Permian Basin. The company went public in 2012 and has established itself as a top-tier independent producer through disciplined acquisition and operational excellence. The company's most transformational transaction occurred in September 2024 with the completion of its $26 billion merger with Endeavor Energy Resources, which added around 470,000 net acres and doubled Diamondback's total acreage position. Diamondback boasts an enviable position in the Midland sub-basin, with some of the lowest unit costs among its Permian peers.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.